Thymalin vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Thymalin is a polypeptide complex isolated from calf thymus glands (developed by the Russian Gerontology Institute), shown to restore immune function, extend lifespan, and reverse thymic involution. Clinical studies demonstrate improved immune parameters and up to 40% reduction in mortality in elderly patients.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Not well characterized as a complex extract; individual peptides have varying kinetics
- ~7 days
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg IM or SC daily
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Once daily
- Once weekly
- Key Benefits
- Restores thymic function and T-cell immunity
- Extends healthy lifespan (documented in long-term studies)
- Reduces infectious disease incidence in elderly
- Normalizes immune parameters in immunodeficiency
- Anti-tumor immune surveillance
- Improves vaccine response in elderly
- Reduces cardiovascular mortality (40% in landmark Russian study)
- Normalizes neuroendocrine function
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Very well tolerated in decades of Russian clinical use
- Mild injection site reactions
- Rare: mild allergic reaction (natural extract)
- Transient flu-like symptoms on initiation (immune activation)
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —